Gruppo FarmaImpresa at the Top of European Quality: Maximum Safety for Gynecologic Well-Being The EU Regulation 2017/745 (MDR) is Europe’s most stringent framework for manufacturing and marketing medical devices. It raises the bar on safety, quality, and traceability, introducing far stricter requirements than previous directives. For Gruppo FarmaImpresa, obtaining MDR certification for the Class IIb…
Clinically Proven Effectiveness of Our Hyaluronic Acid-Based Vaginal Medical Device for Women’s Intimate Health Gruppo FarmaImpresa is proud to share the results of its clinical study, conducted on the medical device Revaginal Ovules. The study evaluated the safety and effectiveness of our vaginal ovules in promoting vaginal and uterine tissue regeneration, offering an innovative and…
Vaginal Suppository with Boric Acid for Intimate Well-Being We are pleased to announce the recent registration of our vaginal suppository with the Ministry of Health and Prevention of the United Arab Emirates. Formulated as a medical device, it provides restoration of protection, hydration, and pH balance. Its triple antibacterial, antifungal, and antimicrobial action helps prevent…
Effective vaginal relief: medical device registered in Vietnam for women’s well-being GFI proudly announces that we have successfully registered a Class IIa medical device in Vietnam, formulated with natural ingredients. This device is a vaginal ovule composed of hyaluronic acid, lactic acid, Centella Asiatica, calendula, chamomile, and tea tree oil. Indicated to addressing a wide…
Treatment for Vulvovaginal Mycotic Infections: FarmaImpresa Group certifies a new Medical Device in Macedonia We have completed the registration with the competent authorities in Macedonia for a Class I medical device, designed for the treatment of vulvovaginal mycotic infections. The medical device is formulated as a vaginal suppository based on hyaluronic acid, boric acid, and…